Dennis Joseph Slamon MD
Breast Cancer, Hematologic Oncology
UCLA School of Medicine
Join to View Full Profile
200 Medical 530 420 120 Plz# 365Los Angeles, CA 90095
Phone+1 310-825-5193
Fax+1 310-267-2301
Dr. Slamon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1981
University of ChicagoResidency, Internal Medicine, 1975 - 1979
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1975
Certifications & Licensure
IL State Medical License 1976 - Present
CA State Medical License 1979 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1988
- Super Doctor SuperDoctors.com
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
- Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
- A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide Start of enrollment: 2017 Sep 05
Publications & Presentations
PubMed
- Health-related quality of life in patients with HR+/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the NATALEE...Peter A Fasching, Dennis Slamon, Zbigniew Nowecki, Bozena Kukielka-Budny, Daniil Stroyakovskiy
Clinical Cancer Research. 2025-02-28 - 1 citationsEarly Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers.Jamie E Medina, Akshaya V Annapragada, Pien Lof, Sarah Short, Adrianna L Bartolomucci
Cancer Discovery. 2025-01-13 - Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies.Maggie Chon U Cheang, Mothaffar Rimawi, Stephen Johnston, Samuel A Jacobs, Judith Bliss
NPJ Breast Cancer. 2024-06-29
Lectures
- NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor recept...2019 ASCO Annual Meeting - 6/1/2019
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast CancerUniversity of California, Costa Mesa, California - 5/17/2013
- Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2â€) advanced breast cancer (ABC): Results from MO...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Including Biomarkers and Patient Preference in Treatment DecisionsMarch 24th, 2025- Caught in the Crossfire: The Critical Threats Facing Cancer Centers, Research, and Patient CareMarch 21st, 2025
- UCLA Health Builds on Development of Breakthrough Targeted Therapies to Treat Breast CancerJanuary 16th, 2025
- Join now to see all
Grant Support
- Cru - Clinical Research Unit Shared ResourceNational Cancer Institute2009–2012
- The Transcription Factor SLUG May Drive The Progression Of AKT And Her2/NeuNational Cancer Institute2010–2011
- Signal Transduction In OncogenesisNational Cancer Institute1995–2006
- Academic Training In Medical OncologyNational Cancer Institute1991–2005
- Core--Tissue BankNational Cancer Institute2002
- Her-2/Neu Alterations In Breast And Ovarian CancerNational Cancer Institute1995–2002
- Phase I Study In Patients With Peritoneal Carcinomatosis Using Sch58500National Center For Research Resources1999–2001
- Advances In Human Breast And Prostate CancerNational Cancer Institute2000
- Phase I Study In Patients With Peritoneal CarcinomatosisNational Center For Research Resources1998
- Clinical Cancer Research DevelopmentNational Cancer Institute1994–1996
- Oncogenes In Physiologic And Pathologic StatesNational Cancer Institute1985–1996
- Medical OncologyNational Cancer Institute1992–1995
- Specialized Program Of Research Excellence/Breast CancerNational Cancer Institute1992–1994
- A Program In Medical OncologyNational Cancer Institute1993
- Academic Training In HematologyNational Institute Of Diabetes And Digestive And Kidney Diseases1992–1993
- UCLA Clinical Cancer Research DevelopmentNational Cancer Institute1992–1993
- Clinical Studies Of Biological Response ModifiersDivision Of Cancer Treatment1991–1993
- Oncogenes In Physiologic &Pathological StatesNational Cancer Institute1987–1988
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
